Testicular Tumors: High Likelihood of Cure With Interdisciplinary Management

Standard

Testicular Tumors: High Likelihood of Cure With Interdisciplinary Management. / Krege, Susanne; Oing, Christoph; Bokemeyer, Carsten.

in: DTSCH ARZTEBL INT, Jahrgang 120, Nr. 49, 08.12.2023, S. 843-854.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungFortbildungsbeitragForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{d5f363d27d6e433bbb0f61790f8ff828,
title = "Testicular Tumors: High Likelihood of Cure With Interdisciplinary Management",
abstract = "BACKGROUND: Germ-cell tumors of the testes are the most common type of malignant tumor in men aged 20 to 40. Their incidence in Germany is 10 per 100 000 men per year, with an estimated 4200 new cases annually.METHODS: This selective review is based on the recommendations of the German clinical practice guideline on the diagnosis, treatment and follow-up care of testicular germ-cell tumors, as well as on pertinent original articles and reviews.RESULTS: The treatment of germ-cell tumors requires an interdisciplinary approach comprising resection of the affected testis followed by further steps that depend on the histological type and stage of the tumor, which may include active surveillance, chemotherapy, radiotherapy, further surgery, or some combination of these measures. Two-thirds of germ-cell tumors are diagnosed in clinical stage I, when they are still confined to the testis; one-third are already metastatic when diagnosed, with organ metastases in 10-15%. Stage-based multimodal treatment approaches are associated with cure rates of more than 99% for stage I tumors and 67-95% for advanced metastatic disease, depending on the degree of progression.CONCLUSION: For patients with early-stage tumors, overtreatment should be avoided in order to minimize long-term sequelae. For those whose tumors are in advanced stages, it must be decided which patients should receive intensified treatment to optimize the outcome. Multimodal treatment approaches are associated with high cure rates even for patients with metastatic disease.",
keywords = "Combined Modality Therapy, Disease Progression, Germany/epidemiology, Humans, Male, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms/diagnosis",
author = "Susanne Krege and Christoph Oing and Carsten Bokemeyer",
year = "2023",
month = dec,
day = "8",
doi = "10.3238/arztebl.m2023.0143",
language = "English",
volume = "120",
pages = "843--854",
journal = "DTSCH ARZTEBL INT",
issn = "1866-0452",
publisher = "Deutscher Arzte-Verlag",
number = "49",

}

RIS

TY - JOUR

T1 - Testicular Tumors: High Likelihood of Cure With Interdisciplinary Management

AU - Krege, Susanne

AU - Oing, Christoph

AU - Bokemeyer, Carsten

PY - 2023/12/8

Y1 - 2023/12/8

N2 - BACKGROUND: Germ-cell tumors of the testes are the most common type of malignant tumor in men aged 20 to 40. Their incidence in Germany is 10 per 100 000 men per year, with an estimated 4200 new cases annually.METHODS: This selective review is based on the recommendations of the German clinical practice guideline on the diagnosis, treatment and follow-up care of testicular germ-cell tumors, as well as on pertinent original articles and reviews.RESULTS: The treatment of germ-cell tumors requires an interdisciplinary approach comprising resection of the affected testis followed by further steps that depend on the histological type and stage of the tumor, which may include active surveillance, chemotherapy, radiotherapy, further surgery, or some combination of these measures. Two-thirds of germ-cell tumors are diagnosed in clinical stage I, when they are still confined to the testis; one-third are already metastatic when diagnosed, with organ metastases in 10-15%. Stage-based multimodal treatment approaches are associated with cure rates of more than 99% for stage I tumors and 67-95% for advanced metastatic disease, depending on the degree of progression.CONCLUSION: For patients with early-stage tumors, overtreatment should be avoided in order to minimize long-term sequelae. For those whose tumors are in advanced stages, it must be decided which patients should receive intensified treatment to optimize the outcome. Multimodal treatment approaches are associated with high cure rates even for patients with metastatic disease.

AB - BACKGROUND: Germ-cell tumors of the testes are the most common type of malignant tumor in men aged 20 to 40. Their incidence in Germany is 10 per 100 000 men per year, with an estimated 4200 new cases annually.METHODS: This selective review is based on the recommendations of the German clinical practice guideline on the diagnosis, treatment and follow-up care of testicular germ-cell tumors, as well as on pertinent original articles and reviews.RESULTS: The treatment of germ-cell tumors requires an interdisciplinary approach comprising resection of the affected testis followed by further steps that depend on the histological type and stage of the tumor, which may include active surveillance, chemotherapy, radiotherapy, further surgery, or some combination of these measures. Two-thirds of germ-cell tumors are diagnosed in clinical stage I, when they are still confined to the testis; one-third are already metastatic when diagnosed, with organ metastases in 10-15%. Stage-based multimodal treatment approaches are associated with cure rates of more than 99% for stage I tumors and 67-95% for advanced metastatic disease, depending on the degree of progression.CONCLUSION: For patients with early-stage tumors, overtreatment should be avoided in order to minimize long-term sequelae. For those whose tumors are in advanced stages, it must be decided which patients should receive intensified treatment to optimize the outcome. Multimodal treatment approaches are associated with high cure rates even for patients with metastatic disease.

KW - Combined Modality Therapy

KW - Disease Progression

KW - Germany/epidemiology

KW - Humans

KW - Male

KW - Neoplasms, Germ Cell and Embryonal

KW - Testicular Neoplasms/diagnosis

U2 - 10.3238/arztebl.m2023.0143

DO - 10.3238/arztebl.m2023.0143

M3 - Training articles

C2 - 37378600

VL - 120

SP - 843

EP - 854

JO - DTSCH ARZTEBL INT

JF - DTSCH ARZTEBL INT

SN - 1866-0452

IS - 49

ER -